https://www.selleckchem.com/pr....oducts/piceatannol.h
Few data are available on plasma concentrations of antiretroviral therapy (ARV) during intermittent treatment. To compare plasma concentrations in OFF vs ON treatment periods at several time points during treatment. During a successful 48-week multicenter study (ANRS 162-4D trial) of 4 days with treatment (ON) followed by 3 days without treatment (OFF) in adults treated by two nucleoside analogues and a third agent belonging to a boosted protease-inhibitor (PI, darunavir [DRV], atazanavir [ATV], lopinavir [LPV]) or a non-nucleoside-